Latest Development Program News

Encounter Resources reports significant extensions of shallow, high-grade niobium mineralisation east of its Green Mineral Resource Estimate at the Aileron Project, with promising drill results and a major development program planned for 2026.

Locksley Resources has launched an Expression of Interest process to select a leading U.S. engineering firm for the Desert Antimony Mine pilot plant design, marking a critical step toward establishing a domestic antimony supply chain aligned with federal priorities.

Torque Metals has raised $15 million in a placement led by top-tier global investors, setting the stage for an aggressive drilling campaign at its Paris Gold Project in Western Australia.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Island Pharmaceuticals has submitted critical responses to the FDA, advancing the development of its antiviral Galidesivir under the Animal Rule pathway. The company awaits FDA feedback expected by early January 2026, setting the stage for upcoming Marburg virus studies.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Entropy Neurodynamics has successfully administered its proprietary IV-infused psilocin, TRP-8803, to the first patient in a clinical trial targeting Binge Eating Disorder, marking a world first in neuropsychiatric treatment.

Metal Bank Limited is set to complete its acquisition of Hastings Technology Metals' gold assets, bolstering its Western Australia portfolio and appointing Tim Gilbert as CEO to drive its transition from explorer to producer.

Hexima Limited reveals plans to return capital to shareholders and restructure its board following the closure of its main clinical program and prolonged ASX trading suspension.